Pyrithioxin
Based on 2 publication(s) in Google Scholar
Pyrithioxin (Pyritinol) is an orally active neurodynamic compound. Pyrithioxin can promote the metabolism of glucose and amino acids, increase carotid blood flow and improve cerebral blood flow. Pyrithioxin exhibits anti-inflammation, anti-tumor and neuroprotective effect. Pyrithioxin can be used for the researches of cancer, inflammation, immunology, metabolic and neurological disease such as cerebral infarct, epilepsy, fibrosarcomas and rheumatoid polyarthritis.
For research use only. We do not sell to patients.
- CAS No.: 1098-97-1
- Formula: C16H20N2O4S2
- Molecular Weight:368.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Pyrithioxin
More
Biological Activity
Description
In Vitro
Pyrithioxin (dihydrochloride) (0.5-3 μg/mL) increases D-arabitol production from Candida parapsilosis by regulating glucose-6-phosphate dehydrogenase[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Pyrithioxin (200 and 600 mg/kg diet, added to the feed for free consumption, 6 weeks) elevates acetylcholine levels and enhances memory behavior in rats[4].
Pyrithioxin (50-200 mg/kg, p.o.) reduces flinching behavior in Streptozocin (HY-13753)-induced diabetic rats[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WISTAR rats with 3-MC-induced subcutaneous fibrosarcomas[2]
-
Dosage:20 mg/kg
-
Administration:Orally gavage, five times a week after tumor appearance or after tumor resection
-
Result:Showed remission rate 11%-12%.
Partial recurrence control was achieved in remitted rats with small tumors (0.7-1 cm in diameter) under continuous administration.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1098-97-1
-
Appearance Solid
-
Molecular Weight 368.47
-
Formula C16H20N2O4S2
-
Color Off-white to light yellow
-
SMILES
OCC1=C(CSSCC2=C(CO)C(O)=C(C)N=C2)C=NC(C)=C1O
-
Synonyms
Pyritinol; Pyridoxine disulfide; Vitamin B6 disulfide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
INSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis. [Abstract]2026 Mar 15;17(1):4002. PMID: 41833955 -
Int J Biol Macromol
Unveiling the mechanistic link between peroxiredoxin inhibition and ferroptosis-like cell death induced by Dinaciclib in Entamoeba histolytica. [Abstract]2026 Mar:350:150992. PMID: 41713546
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Stoica E, et al. Facilitation through hyperventilation of therapeutic effect of pyrithioxin in cerebral infarct patients. Eur Neurol. 1975;13(4):285-303. [Content Brief]
[2]. von Metzler A. et al. [Antineoplastic activity of drugs affecting the central nervous system against chemically induced tumors in the rat (author's transl)]. J Cancer Res Clin Oncol. 1979 Sep;95(1):11-8. German. [Content Brief]
[3]. Crouzet J, et al. Pyrithioxine et polyarthrite rhumatoïde [Pyrithioxin and rheumatoid polyarthritis]. Rev Rhum Mal Osteoartic. 1986 Jan;53(1):45-8. [Content Brief]
[4]. Marston HM, et al. Effects of the chronic administration of pyrithioxin on behaviour and cholinergic function in young and aged rats. J Psychopharmacol. 1987 Jan;1(4):237-43. [Content Brief]
[5]. Zheng S, et al. Combined mutagenesis and metabolic regulation to enhance D-arabitol production from Candida parapsilosis. J Ind Microbiol Biotechnol. 2020 May;47(4-5):425-435. [Content Brief]
[6]. Martínez-Lage JM, et al. Asociación de piritioxina y difenilhidantoina, en el tratamiento de los síndromes epilépticos orgánicos [Association of pyrithioxin and diphenylhydantoin in the treatment of organic epileptic syndromes]. Med Clin (Barc). 1965 Sep;45(3):204-5. [Content Brief]
[7]. Jiménez-Andrade GY, et al. Pyritinol reduces nociception and oxidative stress in diabetic rats. Eur J Pharmacol. 2008 Aug 20;590(1-3):170-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)